<DOC>
	<DOCNO>NCT02696850</DOCNO>
	<brief_summary>The goal research project explore impact addition budesonide high-volume , low-pressure nasal sinus saline irrigation ( aka `` Neti-Pot '' -type system ) patient chronic rhinosinusitis without nasal polyp .</brief_summary>
	<brief_title>The Impact Of The Addition Of Budesonide To Low-Pressure , High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis</brief_title>
	<detailed_description>Study Design Double-blind placebo-controlled randomize clinical trial Subjects Up 80 adult patient complaint purulent ( clear ) nasal drainage accompany nasal obstruction , facial pain-pressure-fullness , reduction loss smell 12 week great . Inclusion Criteria : Twelve ( 12 ) week longer two follow sign symptom consistent chronic rhinosinusitis ( CRS ) : mucopurulent drainage ( anterior , posterior , ) , nasal obstruction ( congestion ) , facial pain-pressure-fullness , decrease sense smell AND inflammation document one follow finding : - purulent ( clear ) mucus edema middle meatus ethmoid region , - polyp nasal cavity middle meatus , and/or - radiographic image show inflammation paranasal sinuses Exclusion criterion : - Unable speak English - History comorbid ciliary dyskinesia , cystic fibrosis mucociliary condition - Dependence prolong corticosteroid therapy comorbid condition , asthma chronic obstructive pulmonary disease . - History oral systematic antibiotic use past 2 week - History nasal sinus surgery within past 6 week - History cerebrospinal fluid leak - History allergy budesonide topical steroid - Pregnant breast feed - Current infection history one follow infection : Tuberculosis ( TB ) lung infection , Herpes infection eye . - Baseline SNOT-22 total score 9 exclude due inability achieve minimally clinically improve difference Variables Interest Demographic - age , gender , race . Index condition - Duration CRS symptom , response previous treatment Co-morbid condition - Presence severity general comorbid condition assess ACE-27 . Presence rhinosinusitis-specific comorbidities include : inhalant allergy , asthma , aspirin sensitivity Previous sinus and/or nasal surgery - Previous sinus and/or nasal surgery , include functional endoscopic sinus surgery , turbinate reduction , septoplasty capture duration since surgery time enrollment . Randomization The study statistician , Dr. Dorina Kallogjeri , use randomize block design study drug assignment . To ensure balance key clinical feature think related outcome , subject stratify one four category base two main clinical feature : nasal polyp ( presence/absence ) history previous sinus surgery ( yes/no ) prior randomization . Intervention The study intervention budesonide powder ( 0.5 mg/capsule ) identical-appearing placebo product contain lactose . All subject provide 8-ounce ( 240 ml ) NeilMed Sinus Rinse Regular Bottle Kit one-month supply USP Grade Sodium Chloride &amp; Sodium Bicarbonate Mixture ( pH balance , Isotonic &amp; Preservative &amp; Iodine Free ) commercially prepared packettes . Subjects may substitute NeilMed Sinus Rinse Regular Bottle Kit nasal irrigation system , opinion Principal Investigator , similar NeilMed system embody low-pressure , high-volume concept nasal irrigation . Subjects need purchase distilled water boil tap water five minute use saline irrigation . Subjects require dissolve content two capsule 8-ounce ( 240 ml ) NeilMed Sinus Rinse Regular Bottle along saline rinse . All subject instruct irrigate right leave nasal cavity one-half content nasal rinse daily . The subject receive write instruction video prior initiation intervention ensure proper delivery . Each study bottle contain 60 capsule Budesonide placebo assign number 1-80 . Only Dr. Kallogjeri ( biostatistician ) list link treatment type ( Budesonide placebo ) bottle number . The bottle number correspond randomization schedule provide Dr. Kallogjeri . The subject rest study team remain blind randomization assignment . The subject rest study team know bottle number assign , treatment contain bottle . Dr. Kallogjeri biostatistician study otherwise involved participant . In event Serious Adverse Event determine PI necessitate breaking blind , intervention assignment reveal Dr. Kallogjeri medical staff doctor care patient . In event Dr. Kallogjeri unable reach time need , assure safety subject , blind broken Sara Kukuljan , RN , Drs . Piccirillo Schneider information share medical staff assume care patient . The active drug placebo prepared Genesis Pharmacy , St. Louis Missouri deliver Clinical Outcomes Office product store locked cabinet . The cost sufficient budesonide study duration ( i.e. , 60 budesonide capsule ) $ 75 cost sufficient quantity lactose capsule $ 25 . Budesonide Budesonide anti-inflammatory glucocorticoid steroid use variety common ailment . Among condition related respiratory tract , budesonide use inhalational drug treatment asthma , COPD , allergic rhinitis , nasal polyp . The mechanism action budesonide similar corticosteroid include wide range inhibitory activity multiple cell type ( e.g. , mast cell , eosinophil , neutrophil , macrophage lymphocyte ) mediator ( eg , histamine , eicosanoids , leukotrienes , cytokine ) involve allergic- non-allergic-mediated inflammation . ( AstraZeneca 2000 ) Subjects randomize budesonide intervention arm require mix 1.0 mg ( provide two capsule contain 0.5 mg budesonide ) budesonide sinus rinse bottle rinse nasal cavity one half bottle ( ~ 4 ounce ~120 ml ) daily . The inert ingredient : loxasperse powder , increase solubility dispersibility budesonide microbiologically safe ; mannitol , widely use pharmaceutical product capsule diluent ; Xylifos™ powder , proprietary powder excipient use safely pharmaceutical compound nasal nebulization nasal irrigation . Placebo The placebo product contain lactose monohydrate supply clear plastic capsule , identical budesonide capsule . The lactose capsule contain lactose ingredient . Concomitant Medications At time enrollment , subject expect already use topical nasal steroid medication ( ie. , fluticasone Flonase® ) . Subjects currently use topical nasal steroid spray ask continue medication . Topical nasal steroid spray indicate therapy CRS consider experimental . Subjects currently use topical steroid spray ask initiate therapy duration study , unless medical reason use .</detailed_description>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Twelve ( 12 ) week longer two follow sign symptom consistent chronic rhinosinusitis ( CRS ) • mucopurulent drainage ( anterior , posterior , ) , nasal obstruction ( congestion ) , facial painpressurefullness , decrease sense smell AND inflammation document one follow finding : purulent ( clear ) mucus edema middle meatus ethmoid region , polyp nasal cavity middle meatus , and/or radiographic image show inflammation paranasal sinuses Unable speak English History comorbid ciliary dyskinesia , cystic fibrosis mucociliary condition Dependence prolong corticosteroid therapy comorbid condition , asthma chronic obstructive pulmonary disease . History oral systematic antibiotic use past 2 week History nasal sinus surgery within past 6 week History cerebrospinal fluid leak History allergy budesonide topical steroid Pregnant breast feed Current infection history one follow infection : Tuberculosis ( TB ) lung infection , Herpes infection eye . Baseline SNOT22 total score 9 exclude due inability achieve minimally clinically improve difference</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>sinusitis</keyword>
	<keyword>rhinosinusitis</keyword>
	<keyword>rhinitis</keyword>
	<keyword>nasal lavage</keyword>
</DOC>